Bcl 2 Modifing Factor, NT, Blocking Peptide (Bmf)
Catalog No : USB-B0807-09P
367.83€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Bcl 2 Modifing Factor, NT, Blocking Peptide (Bmf) | ||
|---|---|---|---|
| Catalog No | USB-B0807-09P | ||
| Supplier’s Catalog No | B0807-09P | ||
| Supplier | US Biologicals | ||
| Source antigen | Synthetic peptide | ||
| Reactivity | |||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | |||
| Storage | -20°C | ||
|---|---|---|---|
| Other names | |||
| Grade | Purified | ||
| Purity | Purified 60-70% | ||
| Form | Supplied as a lyophilized powder. | ||
| Reactivity life | 12 months | ||
| Note | For reserch purpose only | ||
| Purity | Purified 60-70% | ||
| Description | Synthetic peptide (EPSQCVEELEDDV) corresponding to amino acids 2 to 14 of human Bmf (1). This sequence differs from that of mouse by one amino acid. Apoptosis is related to many diseases and development. Members in the Bcl-2 family are critical regulators of apoptosis by either inhibiting or promoting cell death. Bcl-2 homology 3 (BH3) domain is a potent death domain. BH3-only proteins, including Bad, Bid, Bik, Hrk, Bim, Noxa, and PUMA, form a growing subclass of the Bcl-2 family. A novel BH3-only protein was recently identified in human and mouse and designated Bmf (for Bcl-2-modifing factor) (1). The BH3 domain in Bmf is required both for binding to Bcl-2 proteins and for triggering apoptosis. In healthy cells, Bmf associates with the dynein light chain 2 (DLC2) component of the myosin V motors and is sequestered by the cell’s actin cytoskeleton. Disruption of the actin cytoskeleton, either by depolymerization of actin filaments or by detachment of cells from the extracellular matrix, triggers release and activation of Bmf, initiating the downstream apoptotic program (1,2). Bmf is constitutively expressed in many tissues (1,2). Applications: Suitable for use in ELISA and Western Blot. Other applications not tested. Storage and Stability: Lyophilized powder may be stored at -20°C. Reconstitute to nominal volume by adding sterile 25% glycerol and store at -20°C. May be stored at 4°C for short-term only. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. | ||
Product Details
© 2020 Imugex All Rights Reserved